MMP-9基因rs17576位点多态性与汉族女性乳腺癌易感性的相关性
摘要
目的探讨基质金属蛋白酶-9 (MMP-9)基因rs17576位点多态性与汉族女性乳腺癌易感性的相关性。方法收集2013-2016年黑龙江省齐齐哈尔和大庆地区的282例乳腺癌患者和302例对照组女性,计算两组等位基因及基因型频率。结果两组MMP-9基因rs17576位点等位基因和基因型分布比较差异均有统计学意义(均P<0. 05)。校正混杂因素后,基因型AA和显性模型下对乳腺癌的风险预测值分别为2. 869 (95%CI:1. 512～5. 447,P=0. 001)和2. 809 (95%CI:1. 513～5. 214,P=0. 001)。3组肿瘤分期和淋巴结转移阳性率比较差异均有统计学意义(均P<0. 05),3组肿瘤大小、雌激素受体阳性率、孕激素受体阳性率和病理分型比较差异均无统计学意义(均P>0. 05)。结论 MMP-9基因rs17576位点多态性与乳腺癌易感性存在一定相关性,AA基因型是乳腺癌发病的危险因素,rs17576位点多态性与乳腺癌淋巴结转移和肿瘤分级具有相关性。本研究所取得的阶段性数据可以为本地区女性群体乳腺癌易感基因的筛选及发病风险评估提供前期研究数据,为乳腺癌的个体化防治和诊断做出贡献。
引文
[1] Fan L,Strasser-Weippl K,Li JJ,et al. Breast cancer in China[J]. Lancet Oncol,2014,15(7):279-289.
[2] Zhang B,Beeghly-Fadiel A,Long J,er al. Genetic variants associated with breast-cancer risk:comprehensive research synopsis,meta-analysis, and epidemiological evidence[J]. Lancet Oncol,2011,12(5):477-488.
[3] Long J,Cai Q,Sung H,et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer[J].PLo S Genet,2012,8(2):e1002532.
[4] Sotiriou C,Pusztai L. Gene-expression signatures in breast cancer[J]. N Engl J Med,2009,360(8):790-800.
[5] Gonzalez-Villasana V,Fuentes-Mattei E,Ivan C,et al. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer[J]. Clin Cancer Res,2015,21(9):2127-2137.
[6] Wang X,Yu YY,Lieu S,et al. MMP9 regulates the cellular response to inflammation after skeletal injury[J]. Bone,2013,52(1):111-119.
[7] Chahil JK,Munretnam K,Samsudin N,et al. Genetic polymorphisms associated with breast cancer in malaysian cohort[J]. Ind J Clin Biochem,2015,30(2):134-139.
[8] Farina AR,Mackay AR. Gelatinase B/MMP-9 in tumour pathogenesis and progression[J]. Cancers,2014,6(1):240-296.
[9] Jones JL,Walker RA. Control of matrix metalloproteinase activity in cancer[J]. J Pathol,1997,183(4):377-379.
[10] Merdad A,Karim S,Schulten HJ,et al. Expression of matrix metalloproteinases(MMPs)in primary human breast cancer:MMP-9as a potential biomarker for cancer invasion and metastasis[J].Anticancer Res,2014,34(3):1355-1366.
[11] Liu D,Guo H,Li Y,et al. Association between polymorphisms in the promoter regions of matrix metalloproteinases(MMPs)and risk of cancer metastasis:a meta-analysis[J]. PLo S One,2012,7(2):e31251.
[12] Bartsch JE,Staren ED,Appert HE. Matrix metalloproteinase expression in breast cancer[J]. J Surg Res,2003,110(2):383-392.
[13] Pellikainen JM,Ropponen KM,Kataja VV,et al. Expression of matrix metalloproteinase(MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2,HER2,and prognosis[J]. Clin Cancer Res,2004,10(22):7621-7628.
[14] Song J,Su H,Zhou YY,et al. Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients:a meta-analysis[J]. Asian Pac J Cancer Prev,2013,14(3):1615-1621.
[2] Zhang B,Beeghly-Fadiel A,Long J,er al. Genetic variants associated with breast-cancer risk:comprehensive research synopsis,meta-analysis, and epidemiological evidence[J]. Lancet Oncol,2011,12(5):477-488.
[3] Long J,Cai Q,Sung H,et al. Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer[J].PLo S Genet,2012,8(2):e1002532.
[4] Sotiriou C,Pusztai L. Gene-expression signatures in breast cancer[J]. N Engl J Med,2009,360(8):790-800.
[5] Gonzalez-Villasana V,Fuentes-Mattei E,Ivan C,et al. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer[J]. Clin Cancer Res,2015,21(9):2127-2137.
[6] Wang X,Yu YY,Lieu S,et al. MMP9 regulates the cellular response to inflammation after skeletal injury[J]. Bone,2013,52(1):111-119.
[7] Chahil JK,Munretnam K,Samsudin N,et al. Genetic polymorphisms associated with breast cancer in malaysian cohort[J]. Ind J Clin Biochem,2015,30(2):134-139.
[8] Farina AR,Mackay AR. Gelatinase B/MMP-9 in tumour pathogenesis and progression[J]. Cancers,2014,6(1):240-296.
[9] Jones JL,Walker RA. Control of matrix metalloproteinase activity in cancer[J]. J Pathol,1997,183(4):377-379.
[10] Merdad A,Karim S,Schulten HJ,et al. Expression of matrix metalloproteinases(MMPs)in primary human breast cancer:MMP-9as a potential biomarker for cancer invasion and metastasis[J].Anticancer Res,2014,34(3):1355-1366.
[11] Liu D,Guo H,Li Y,et al. Association between polymorphisms in the promoter regions of matrix metalloproteinases(MMPs)and risk of cancer metastasis:a meta-analysis[J]. PLo S One,2012,7(2):e31251.
[12] Bartsch JE,Staren ED,Appert HE. Matrix metalloproteinase expression in breast cancer[J]. J Surg Res,2003,110(2):383-392.
[13] Pellikainen JM,Ropponen KM,Kataja VV,et al. Expression of matrix metalloproteinase(MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2,HER2,and prognosis[J]. Clin Cancer Res,2004,10(22):7621-7628.
[14] Song J,Su H,Zhou YY,et al. Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients:a meta-analysis[J]. Asian Pac J Cancer Prev,2013,14(3):1615-1621.